Your browser doesn't support javascript.
loading
Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor.
Mellergaard, Maiken; Skovbakke, Sarah Line; Jepsen, Stine Dam; Panagiotopoulou, Nafsika; Hansen, Amalie Bøge Rud; Tian, Weihua; Lund, Astrid; Høgh, Rikke Illum; Møller, Sofie Hedlund; Guérillot, Romain; Hayes, Ashleigh S; Erikstrup, Lise Tornvig; Andresen, Lars; Peleg, Anton Y; Larsen, Anders Rhod; Stinear, Timothy P; Handberg, Aase; Erikstrup, Christian; Howden, Benjamin P; Goletz, Steffen; Frees, Dorte; Skov, Søren.
Afiliação
  • Mellergaard M; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Skovbakke SL; Biotherapeutic Glycoengineering and Immunology, DTU Bioengineering, Department of Biotechnology and Biomedicine, Technical University of Denmark , Lyngby, Denmark.
  • Jepsen SD; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Panagiotopoulou N; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Hansen ABR; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Tian W; Biotherapeutic Glycoengineering and Immunology, DTU Bioengineering, Department of Biotechnology and Biomedicine, Technical University of Denmark , Lyngby, Denmark.
  • Lund A; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Høgh RI; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Møller SH; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Guérillot R; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria, Australia.
  • Hayes AS; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria, Australia.
  • Erikstrup LT; Department of Clinical Microbiology, Aarhus University Hospital , Aarhus, Denmark.
  • Andresen L; Department of Veterinary and Animal Sciences, Laboratory of immunology, Section for Preclinical Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark.
  • Peleg AY; Department of Microbiology, Monash University , Melbourne, Victoria, Australia.
  • Larsen AR; Department of Microbiology, Infection Program, Monash Biomedicine Discovery Institute, Monash University , Melbourne, Victoria, Australia.
  • Stinear TP; Centre to Impact Antimicrobial Resistance, Monash University , Melbourne, Victoria, Australia.
  • Handberg A; Statens Serum Institute, Microbiology and Infection Control , Copenhagen, Denmark.
  • Erikstrup C; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria, Australia.
  • Howden BP; Department of Clinical Biochemistry, Aalborg University Hospital, North Denmark Region , Aalborg, Denmark.
  • Goletz S; Department of Clinical Medicine, Aalborg University , Aalborg, Denmark.
  • Frees D; Department of Clinical Immunology, Aarhus University Hospital , Aarhus, Denmark.
  • Skov S; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity , Melbourne, Victoria, Australia.
mBio ; 14(5): e0134923, 2023 Oct 31.
Article em En | MEDLINE | ID: mdl-37796131
ABSTRACT
IMPORTANCE Therapies that target and aid the host immune defense to repel cancer cells or invading pathogens are rapidly emerging. Antibiotic resistance is among the largest threats to human health globally. Staphylococcus aureus (S. aureus) is the most common bacterial infection, and it poses a challenge to the healthcare system due to its significant ability to develop resistance toward current available therapies. In long-term infections, S. aureus further adapt to avoid clearance by the host immune defense. In this study, we discover a new interaction that allows S. aureus to avoid elimination by the immune system, which likely supports its persistence in the host. Moreover, we find that blocking the specific receptor (PD-1) using antibodies significantly relieves the S. aureus-imposed inhibition. Our findings suggest that therapeutically targeting PD-1 is a possible future strategy for treating certain antibiotic-resistant staphylococcal infections.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Staphylococcus aureus Resistente à Meticilina Limite: Humans Idioma: En Revista: MBio Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Dinamarca
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Staphylococcus aureus Resistente à Meticilina Limite: Humans Idioma: En Revista: MBio Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Dinamarca